Navigation Links
Rivaroxaban phase III pivotal data presented at EFORT annual meeting
Date:5/30/2008

Nice, France (May 30, 2008) Results from a pivotal Phase III clinical trial presented today demonstrate that rivaroxaban, an oral, once-daily, investigational anticoagulant medication, was superior in preventing venous blood clots in patients who underwent total knee replacement (TKR) surgery. The head-to-head study compared rivaroxaban with the U.S.-approved dosing regimen for enoxaparin, the current standard of care.

Data from the RECORD4 clinical trial were presented at the annual meeting of the European Federation of National Associations of Orthopaedics & Traumatology (EFORT). Rivaroxaban is being jointly developed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. and Bayer HealthCare AG.

The RECORD4 data show that rivaroxaban (10mg once-daily) provided TKR surgery patients a statistically significant 31% relative risk reduction (RRR) in total venous thromboembolism (VTE) events defined in the study as the composite of all deep vein thrombosis, non-fatal pulmonary embolism and all-cause mortality compared to enoxaparin (30mg twice-daily) (6.9% and 10.1%, respectively, p =0.012). Rates of major bleeding, the main safety endpoint, were low in both treatment groups, yet numerically greater in rivaroxaban-treated patients. This difference was not statistically significant from the rate of major bleeding in enoxaparin-treated patients (0.7% and 0.3% respectively; p=0.110). RECORD4 is the third of three, direct, head-to-head comparisons within the RECORD program to demonstrate the superior efficacy of rivaroxaban over enoxaparin with a similar adverse event profile.

"The superior efficacy and similar adverse event profile of rivaroxaban demonstrated in RECORD4 are in line with the outstanding results of the earlier RECORD studies," said Dr. A.G.G. Turpie, Professor of Medicine, McMaster University, Canada and Principal Investigator for the RECORD program. "The success of this trial strengthens my belief that direct Factor Xa inhibition with rivaroxaban has the potential to revolutionize the way we prevent the formation of dangerous blood clots."

RECORD4 is part of the RECORD program (REgulation of Coagulation in major Orthopedic surgery reducing the Risk of DVT and PE), which involved more than 12,500 total hip or knee replacement surgery patients, and is the first RECORD trial to evaluate rivaroxaban against enoxaparin 30mg twice-daily, which is the Food and Drug Administration (FDA)-approved dosing regimen for enoxaparin in knee replacement surgery. The RECORD1, 2 and 3 studies compared rivaroxaban against enoxaparin dosed once-daily at 40mg. The full RECORD data set will be used to support the new drug application for rivaroxaban to the FDA, which is planned for submission in the third quarter 2008.

RECORD4 Study Details

RECORD4 compared rivaroxaban to enoxaparin for the prevention of VTE following TKR surgery in 3,148 patients. Rivaroxaban (10mg once-daily) was orally administered 6-8 hours post surgery, compared to enoxaparin (30mg twice-daily), which was initiated by subcutaneous injection 12-24 hours post surgery. The study achieved its primary endpoint, demonstrating a 31% RRR in total VTE for patients treated with rivaroxaban, compared to those treated with enoxaparin (6.9% and 10.1%, respectively; p = 0.012). The rate of major bleeding, the main safety endpoint, was numerically greater in rivaroxaban-treated patients, yet rates were low in both treatment groups (0.7% in rivaroxaban-treated patients and 0.3% in enoxaparin-treated patients). This difference between treatment groups was not statistically significant (p=0.110). Major VTE (composite of proximal deep vein thrombosis, non-fatal pulmonary embolism and VTE-related death) and symptomatic VTE, secondary efficacy endpoints, occurred less frequently with rivaroxaban, but the differences did not reach statistical significance.

Unmet Needs in Venous Thromboembolism (VTE)

Annually in the U.S., more than 900,000 people suffer from VTE events, and 300,000 people die from VTE. VTE includes deep vein thrombosis (DVT), a blood clot in a deep vein (usually in the leg), and pulmonary embolism (PE), a blood clot in the lungs, both of which are serious, life-threatening but often preventable conditions. These clots often break apart and travel through the bloodstream, blocking blood flow to vital organs.

Patients undergoing major orthopedic surgery are at high risk for VTE because during hip or knee replacement procedures, the large veins of the leg that carry blood back to the heart are damaged, significantly increasing the risk of VTE. In fact, venous blood clots occur in 40-60% of patients undergoing major orthopedic surgery who do not receive preventative care. Each year, approximately 700,000 Americans elect to have hip and knee replacement surgeries, and a blood clot is the most common cause of re-hospitalization for this patient group.


'/>"/>

Contact: Stephen Cooper
stephen.cooper@edelman.com
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. TAK-390MR Phase 3 data presented at Digestive Disease Week
2. Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
3. New AMITIZA 8 mcg phase III studies demonstrated overall symptom improvement in adult women
4. AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
5. Phase III pivotal results presented of VYVANSE to treat ADHD in adults
6. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
7. NicOx Announces U.S. Phase 2a Results for PF-03187207 and Gives an Update on Continuing NO-prostaglandin Program
8. Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting
9. Wal-Mart Launches Phase Three of $4 Prescription Program
10. Sanofi-aventis: Encouraging First-Quarter 2008 Results Further Positive Phase III Results for Eplivanserin
11. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... ... , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... a whole new perspective by using the title layers in ProSlice Levels to ... ProSlice Levels contains over 30 Different presets to choose from. FCPX users ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 26, 2016 Story ... operating models within the health care industry is causing ... efficiency , Deloitte offers a suite of solutions ... issues impacting efficient cost optimization: labor resource analysis, revenue ... services facilitate better outcomes and better economics ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
Breaking Medicine Technology: